Torrent Pharma is reportedly in advanced discussion to buy Unichem Lab’s domestic business. The company’s domestic business generates revenue of around Rs 900 crore. For the domestic assets, the company is likely to offer Rs 3,250 crore. The deal may be announced next week if the talks fructify.
Currently, Unichem Lab is ranked 25th in the domestic market. The company’s operations are 57 percent of its sales and within the domestic business, chronic care business comprises 59 percent of the sales.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
